Author Archives: Patricia Inacio, PhD

Attenuated T-cell Vaccination Helps SLE Patients, Small Trial Shows

  Vaccinating systemic lupus erythematosus (SLE) patients with attenuated T-cells improved their symptoms, according to results of a small controlled trial. It supported previous findings that the vaccination can help lupus patients. The study, “The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation,” was…

Red Blood Cells’ Suicide is Cause for Anemia in SLE, Study Finds

Researchers analyzed blood samples from systemic lupus erythematosus (SLE) patients and found supportive evidence that SLE enhances anemia by promoting the suicidal death of red blood cells. The study “Eryptosis as an Underlying Mechanism in Systemic Lupus Erythematosus-Related Anemia” was published in the journal Cellular Physiology and Biochemistry.

Immune Cell Protein Seen to Prevent Autoimmune Attacks That Lead to SLE

Scientists found a natural protein in immune cells, called CD72, that prevents the abnormal and damaging immune responses characteristic of autoimmune diseases, such as systemic lupus erythematosus (SLE). Findings in the study, “CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm/RNP,” recently published in The…

Cutaneous Lupus Erythematosus Patients May Benefit from JAK1 Inhibitors

Inhibiting a branch of the JAK/STAT signaling pathway may be an effective therapy against cutaneous lupus erythematosus (CLE), according to a recent report. The study, “JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases,” was recently published in PLOS One. A crucial harmful pathway in inflammatory skin diseases,…

Xencor Highlights Potential Lupus Therapy Now in Phase 2 Testing

During the recent Analyst Day event in New York, Xencor highlighted its lead candidate to treat systemic lupus erythematosus (SLE), now in Phase 2 clinical testing, and other potential treatments advancing in development. “We believe our flexible bispecific oncology platform has substantial potential. Our programs are built on a novel XmAb Fc…